基于SVAR模型的我国医药制造业创新投入与产出关系研究

Research on the Relationship between Innovation Input and Output in China's Pharmaceutical Manufacturing Industry Based on SVAR Model

基于2001—2019年相关统计数据构建SVAR模型,采用脉冲响应函数和方差分解等方法实证分析R&D经费、R&D人员、新产品开发经费等创新投入变量对专利申请数和新产品销售收入的影响,以探讨我国医药制造业创新投入与创新产出之间的关系,促进创新资源合理配置。研究结果表明:创新投入与创新产出各变量间存在长期均衡关系,且创新投入对创新产出均有正向的影响,其中R&D经费投入的贡献度最大,R&D人员和新产品开发经费投入对创新产出的影响具有一定的滞后性。因此,有必要加大对R&D经费、R&D人员及新产品开发经费的投入,完善研发融资政策,营造良好的创新环境,引进并培养科技型人才,提高创新投入的产出效率,推动我国医药制造业现代化发展。

To explore the relationship between innovation input and innovation output in China’s pharmaceutical manufacturing industry,and promote the rational allocation of innovation resources.Based on the relevant statistical data from 2001 to 2019,the SVAR model was constructed,and the impact of innovation input variables such as R&D funds,R&D personnel,product development funds on the number of patent applications and new product sales revenue were empirically analyzed by using impulse response function and variance decomposition methods.The results showed that there was a long term equilibrium relationship between innovation input and innovation output variables,and innovation input had a positive impact on innovation output,of which R&D investment had the largest contribution,and R&D personnel and product development investment had a certain lag in the impact of innovation output.Therefore,it is necessary to increase investment in R&D funds,R&D personnel and product development funds,improve R&D financing policies,create a good innovation environment,introduce and cultivate scientific and technological talents,improve the output efficiency of innovation input,and promote the modernization of China’s pharmaceutical manufacturing industry.